|Year : 2010 | Volume
| Issue : 6 | Page : 496-503
Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis
Aparna Shukla, Shilpi Awasthi
Department of Anaesthesia and Critical Care, ERA'S Lucknow Medical College, Lucknow, India
|Date of Web Publication||22-Nov-2010|
Department of Anaesthesia and Critical Care, Era's Lucknow Medical College, Lucknow
Source of Support: None, Conflict of Interest: None
Despite advances in modern medicine, sepsis remains a complex syndrome that has been associated with significant morbidity and mortality. Multiple organ failure associated with sepsis leads to high mortality and morbidity. About 28 - 50% deaths have been reported in patients with sepsis. The number of sepsis patients is increasing, with considerable burden on healthcare facilities. Various factors leading to a rise in the incidence of sepsis are (1) Improvement of diagnostic procedures (2) Increase in the number of immunocompromised patients taking treatment for various autoimmune disease, carcinomas, organ transplantation (3) Advances in intensive procedures (4) Nosocomial infections (5) Extensive use of antibiotics. With the better understanding of sepsis various modalities to modify pathophysiological response of septic patients have developed. Activated protein C and low-dose corticosteroid therapy have been tried in patients, with variable results.
Keywords: Corticosteroid, human recombinant activated protein C (rhAPC), sepsis
|How to cite this article:|
Shukla A, Awasthi S. Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis. Indian J Anaesth 2010;54:496-503
|How to cite this URL:|
Shukla A, Awasthi S. Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis. Indian J Anaesth [serial online] 2010 [cited 2020 Oct 22];54:496-503. Available from: https://www.ijaweb.org/text.asp?2010/54/6/496/72637
| Introduction|| |
Sepsis syndrome, a systemic response to infection, can produce devastating outcomes even in previously normal individuals. Advances in the treatment of sepsis have led to an attempt to elucidate the ideal plan of management in septic patients. Some investigators advocated the use of low-dose corticosteroid therapy,  while others voted for Activated protein C, as soon as the patient arrived in the hospital.  In the past, some researchers have also used high-dose corticosteroids to suppress the inflammatory response in sepsis, but it was not found to be beneficial.  Although in the past few decades, with advancement in medical science, the outcome of septic patients has improved, yet a controversy exists regarding the use of some treatment modalities like Activated protein C and low-dose corticosteroid therapy. Here, in this article, we have discussed a brief pathophysiology of sepsis, the role of these two agents in sepsis management and various research work done on these two agents till the recent past.
| Definition of Sepsis and Severe Sepsis|| |
In 1992, the American College of Chest Physician / Society of Critical Care Medicine have defined sepsis under the following heads: 
SIRS (Systemic inflammatory response syndrome): Altered pathophysiology without positive blood culture.
Sepsis: SIRS induced by infection.
Severe sepsis: Sepsis with dysfunction of at least one organ or organ system.
Septic shock: Severe sepsis with hypotension.
In 2001, the International Sepsis Definition Conference developed another staging system, designated by the acronym PIRO. 
P_ Pre-existing co-morbid conditions that will reduce survival.
I_Insult or infection.
R_Response to infectious challenge.
O_Organ dysfunction or organ failure
| Pathophysiology of Sepsis|| |
Normal haemostasis exists as a finely tuned balance between the coagulation cascade and fibrinolysis, where the blood typically remains in the liquid condition to allow free flow of blood in the vessels, yet clots appropriately to control bleeding. In sepsis there is total disruption of this fine tuning, shifting the balance toward increased coagulation. Endotoxins released from the cell wall of gram negative bacteria cause the activation of factor X, generation of thrombin (factor IIA) and deposition of fibrin (clot) in the microvasculature. Akasa and others,  injected endotoxin in rats and they observed microthombi in hepatic circulation within five minutes. When continuously exposed to endotoxin, there is a deposition of fibrin clots through the microvasculature of the body, resulting in focal areas of hypoperfusion and tissue necrosis thus causing multiple organ dysfunctions.
In normal circumstances whenever there is excessive coagulation, the tissue plasminogen activator generates plasmin from plasminogen, which then lyses the fibrin clots. In sepsis this compensatory mechanism is impaired. Inflammatory cytokines and the thrombin released in sepsis cause inhibition of fibrinolytic enzymes in two ways. First, they activate the platelet and endothelium, to release the plasminogen activator inhibitor; second, the thrombin activates the thrombin activatable fibrinolysis inhibitor. Both these factors inhibit the formation and activation of plasmin and thus impair the fibrinolytic system. 
In normal patients, the formation of thrombin is regulated by the anticoagulant system in the body like protein C, antithrombin and the tissue factor pathway inhibitor. Protein C is converted into activated protein C by the thrombin-thrombomodulin complex, an endothelial cell surface receptor.  Activated protein C then inactivates factor Va and factor VIIIa, which are the key factors in the formation of thrombin. However, in sepsis, due to endothelial injury the level of thrombomodulin on the endothelial surface decreases, thus conversion of protein C to activated protein C is also reduced. ,,
| Management of Severe Sepsis|| |
A. Standard therapy
1. Initial resuscitation: Aggressive fluid resuscitation with either natural / artificial colloids or crystalloids is required during the first six hours. The goals of initial resuscitation of sepsis-induced hypoperfusion should include - (1) Central venous pressure 8-12 mm Hg (2) Mean arterial pressure (MAP)≥65 mm Hg.
2. Early diagnosis and antibiotic treatment: Intravenous antibiotic therapy should be started as early as possible. Appropriate cultures should be obtained before antimicrobial therapy is initiated, if such cultures do not cause significant delay in antibiotic administration. Specific anatomical diagnosis of infection requiring consideration for emergent source control should be sought and diagnosed or excluded as rapidly as possible.
3. Treatment of underlying cause: It may require surgical intervention, such as drainage of abscess, laparotomy and so on.
4. Vasopressors: Norepinephrine or dopamine should be used as first choice vasopressor agents to correct hypotension in septic shock. Low-dose dopamine is not recommended for renal protection.
5. Mechanical ventilation: Invasive or noninvasive ventilatory support may be required in patients in whom pulmonary functions are compromised and they are not able to maintain optimal oxygen saturation.
B. Therapy directed to revert / inhibit pahophysiological response in sepsis
1. Human recombinant activated protein C
2. Low-dose corticosteroid therapy
Human recombinant activated protein C (rh APC)
Food and drug association has approved only one drug till date and that is the human recombinant activated protein C (Drotrecogin alfa), for therapeutic interventions in patients with sepsis.
Protein C, a major physiological anticoagulant is an endogenous protein in humans, encoded by the PROC gene, with the ability to modulate both inflammation and coagulation. Protein C is made in the liver and circulates as a plasma zymogen (an inactive precursor of protease). This vitamin K dependent serine protease enzyme is activated to become APC on the endothelial surface by the thrombin-thrombomodulin complex.  Activated Protein C demonstrates a biphasic half life (t1/2) with a t1/2a and t1/2 b of 13 minutes and 1.63 hours, respectively. Activated Protein C is inactivated by endogenous plasma protease inhibitors. Due to the short half-life and metabolism, rapid elimination of the drug occurs after stopping the infusion. The volume of distribution (Vd) is comparable to the extracellular volume in healthy adults (16 - 20 L).
Chemical formula: C 1786 H 2779 N 509 O 519 S 29M
Molecular Weight: 55,000 gram/mol
Bioavailability: 100% (Intravenous application only)
Metabolism: Endogenous plasma protease inhibitor
Half-life: Less than 2 hours.
Activated protein C has three mechanisms of action:
- Acts as an anti-inflammatory agent: It exerts an anti-inflammatory effect through indirect inhibition of Tumour Necrosis Factor Alfa, by blocking the leucocyte adhesion to selectin and by limiting thrombin-induced inflammatory responses within the vascular endothelium.
- As an anticoagulant agent: Through inhibiting factor Va and factor VIIIa, thus, limiting the thrombin formation.
- As a pro-fibrinolytic agent: Through inhibition of the plasminogen activator inhibitor-1 and decreased activation of the thrombin activatable fibrinolysis inhibitor.
Dosage regimen of activated protein C
Drotrecogin alfa is a lyophilised powder that must be reconstituted prior to dilution. It is stable in 0.9% Normal saline (NS) at a concentration of 100 - 200 mcg/ml. It must be administered through a dedicated intravenous line. It can be administered concurrently with 0.9% normal saline, Ringer's lactate, or dextrose solution through the same line.  It is given in multiple infusions in a total duration of 96 hours, provided the maximum duration of one infusion is not more than 12 hours. The dosage is calculated using the formula:
Mg of drotrecogin=patient weight in kgΧ24 mcg / kg /hourΧ(hours of infusion)/1000
| Adverse Effects and Contraindications|| |
Being a potent anticoagulant, the major adverse effect is an increased risk of bleeding and therefore rhAPC is contraindicated in patients with an increased risk of bleeding. The contraindications are:
- Active internal bleeding
- Recent haemorrhagic shock (within three months)
- Recent intra-cranial or intra-spinal surgery or severe head trauma (within two months)
- Trauma with increased risk of life threatening bleeding
- Presence of epidural catheter
- Intra-cranial neoplasm or mass lesion or evidence of cerebral herniation
| Monitoring Parameters|| |
If there is any evidence of bleeding, periodic haemoglobin, haematocrit, coagulation profile and complete blood picture should be done. As drotrecogin alfa prolongs APTT, it is not a reliable marker of the coagulation profile.
| Precautions|| |
- For percutaneous procedures, the drug should be stopped two hours prior to the procedure and can be started after one hour.
- For elective surgical procedures, the drug should be withheld 12 hours before and 12 hours after the procedure.
- Drug should be stopped at least two hours before the emergency procedure.
- All patients on Drotrecogin alfa should receive stress ulcer prophylaxis, such as histamine-2 antagonists.
- For uncomplicated, less invasive procedures, the drug can be restarted immediately.
- If a patient requires full dose therapeutic heparin or there is evidence of active bleeding, the drug should be stopped immediately.
| Drug Interactions|| |
Human recombinant activated protein C should be used cautiously with other drugs that effect haemostasis concomitantly, such as, aspirin, warfarin and clopidogril; low-dose prophylactic heparin therapy can be given concurrently with drotrecogin.
| Studies on Activated Protein C|| |
Several studies have reported that the level of APC is low in septic patients and these levels predict the outcome. , Taylor and others  conducted a study of gram-negative septicaemia in baboons; administration of APC along with a 100% lethal dose of E. coli prevented the lethality in all the animals tested. When the animals were pre-treated with an antibody specific for activated protein C, the injection of a sub-lethal dose of the organism became 100% lethal.
In July 1998, a multi-center, randomised, double blind, placebo-controlled trial of 1690 patients with severe sepsis was conducted. The trial, which was completed in 2001, is popularly known as the PROWESS (recombinant human activated protein C worldwide evaluation in severe sepsis) trial.  Patients either received drotrecogin alfa at the rate of 24 mcg /kg/hour or placebo for 96 hours of total infusion time. APACHE II (Acute Physiology and Chronic Health Evaluation) was calculated during the 24-hour period, immediately preceding the start of drug administration. Statistical analysis indicated that the 28-day mortality was 30.8% in the placebo group and 24.7% in the drotrecogin alfa group. Thus, there was an absolute risk reduction in the mortality of 6.1%The difference in the mortality between patients given APC and those given placebo was limited to patients with high risk of death, that is, APACHE II scores ≥25. In these groups mortality was reduced from 44% in the placebo group to 31% in the treatment group. However, the efficacy was doubtful in patients with low risk of death (APACHE II<25). Serious bleeding occurred more often in patients receiving drotrecogin alfa (3.5%) than in patients receiving placebo (2%), in the PROWESS trial. The results clearly indicated that one in every five patients who would have died was saved with drotrecogin alfa treatment..
In 2002 the European Medicine Evaluation Agency (EMEA) approved the use of APC in patients with severe sepsis and multiple organ failure with an annual required review. 
In 2005, the ADDRESS trial submitted its report. This trial, required by the FDA, evaluated the standard 24 mcg/kg dose of APC for 96 hours in a double blind, placebo-controlled, multi-center trial, in patients with severe sepsis and APACHE II score<25 or in patients with single organ failure. No significant difference was found in the 28-day mortality (17% placebo versus 18.5% APC, P=0.34). The rate of serious bleeding was 2.4% with APC and 1.2% with placebo, during the infusion period. 
The RESOLVE trial with 240 children getting APC and 237 children getting placebo submitted its report in 2007.  In this trial too, the 28-day mortality rate was not improved significantly (Placebo 17.5% versus APC 17.7%, P=0.39). Unlike the previous studies, the risk of bleeding was equal for placebo and APC (6.8% placebo and 6.7% APC, P=0.97).
The most recent meta-analysis on APC from the Cochrane Database submitted its review in 2008. The review included 4434 adults and 477 paediatric patients and did not find any significant reduction in the 28-day mortality in adults. However, the risk of bleeding was increased. 
On recommendation of FDA another multi-center, placebo-controlled trial has been started to determine the efficacy of APC, called the PROWESS-SHOCK trial. The trial is expected to be completed by the end of 2011. 
After the PROWESS trial, investigators were very enthusiastic about use of APC in all septic patients. Now its use is restricted to selected patients with severe sepsis because of two reasons, (1) cost of treatment with APC is very high, and (2) reduction in the 28-day mortality is not very significant in each and every septic patient.
On the basis of these studies, the SSC guidelines suggested that adult patients with sepsis-induced organ dysfunction associated with a clinical assessment of high risk of death, most of whom will have APACHE II≥25 or multiple organ failure, should receive rhAPC if there are no contraindications (grade 2B except for patients within 30 days of surgery, for whom it will be grade 2C). The SSC guidelines further recommended that adult patients with severe sepsis and low risk of death, most of whom will have APACHE II<20 or one organ failure, should not be given rhAPC (grade 1A). The effects in patients with more than one organ failure, but APACHE II<25 are unclear, and in such circumstances one may use the clinical assessment of the risk of death and the number of organ failures, to support the decision.
| Low-dose Corticosteroid Therapy in Sepsis|| |
In sepsis there is an imbalance between pro-inflammatory and anti-inflammatory cytokines. There is an increase in the concentration of factors IL-1, IL-6 and TNF-α, which are released in abundance from the lymphocytes, macrophages and endothelial cells, during the development of sepsis.  Studies show that NF-kappa B activity was highest in the non-survivors of sepsis. ,
Corticosteroids could reduce the exaggerated inflammatory response in sepsis and prove beneficial by,
- Inhibiting the pro-inflammatory, cytokine-like factor NF-kB, both directly and indirectly. 
- Promoting the production of anti-inflammatory cytokines such as IL-4 and IL-10. Several studies have suggested that the non-survivors of sepsis have a lower concentration of anti-inflammatory cytokines , and a higher concentration of pro-inflammatory cytokines. ,,
- Enhancing the activity of adrenergic receptors.
- Increasing myocardial contractility.
- Corticosteroids inhibit inducible nitric oxide synthetase, a vasodilator molecule.  They also inhibit serum phospholipase A2, resulting in decreased production of vasodilator PG E and prostacycline.  Thus, the overall effect is an increase in blood pressure. 
Adrenal insufficiency in sepsis
Relative adrenal insufficiency and resistance to glucocorticoid may arise during severe sepsis. TNF-alfa and IL-6 decrease cortisol production from the adrenal gland and ACTH production from the pituitary gland. , Average production of cortisol by the adrenal gland is approximately 5.7 mg/m 2 of the body surface per day. In conditions of sepsis, the adrenal gland may produce 150 - 200 mg/m 2 of cortisol daily. If the adrenal glands are exposed to continuous activation by pro-inflammatory cytokines, the glands are exhausted, thereby causing relative or absolute adrenal insufficiency. Relative adrenal insufficiency is more common, seen in 16.3 to 55% of the patients with septic shock. Absolute adrenal insufficiency is seen in only 3% of the patients. ,
Selection and dosages of steroid
The most preferred corticosteroid in sepsis is Hydrocortisone. It is usually given 200 - 300 mg/dl in divided doses or in a continuous infusion. Hydrocortisone is preferred because it is the synthetic equivalent to the physiological final active cortisol. Therefore, treatment with hydrocortisone directly replaces the cortisol independent of metabolic transformation. Another advantage of hydrocortisone is that it has intrinsic mineralocorticoid activity. Annane D  used fludrocortisone in addition to hydrocortisone, but the contribution of the mineralocorticoid to the benefit observed in this trial is unknown. Given that hydrocortisone has some mineralocorticoid activity and absolute adrenal insufficiency is rare in sepsis, and using hydrocortisone by itself has been found to be beneficial, the current guidelines for the treatment of septic shock do not advocate use of fludrocortisone 
Role of steroid therapy in shock reversal
Multiple randomised trials in patients with septic shock confirm that low-dose steroid therapy in these patients improves blood pressure, thereby, causing reduction in vasopressor support. , The postulated mechanisms of the corticosteroid affecting the vascular tone are numerous and cover signal transduction, prostaglandin metabolism, Na+ and Ca+ transport, modulation of adreno-angiotensin, endothelin, mineralocorticoid receptors and inhibition of nitric oxide formation. , In a French multiple-center, a randomised, controlled trial  in 300 patients with severe volume and catecholamine refractory septic shock, low-dose corticosteroid therapy improved survival. This study demonstrated that a low dose of hydrocortisone reduced the risk of death in septic shock patients with relative adrenal insufficiency.
Duration of corticosteroid therapy
Intravenous hydrocortisone (200 - 300 mg/day) for seven days in three-to-four divided doses or continuous infusion is recommended in patients with septic shock, who, despite adequate fluid and vasopressor therapy, are not able to maintain their blood pressure. Minneci and colleagues performed a meta-analysis and found that trials done after 1997, used a median total hydrocortisone dose of 1,209 mg versus 23,975 mg in the earlier trials. The later trials also used a steroid taper.  Gradual tapering of steroid therapy is required because abrupt discontinuation may lead to rebound hypertension and increase in inflammatory response. 
Adverse effects of corticosteroid therapy
- Worsening of infection that initiated sepsis
- Development of super-infections
- Gastrointestinal bleeding
However, most of these side effects are seen with high-dose corticosteroid therapy. Annane and colleagues performed a meta-analysis on steroid therapy. In data collected from 12 trials, in 1705, a patient's risk of superinfections in the corticosteroid group was not increased; 1321 patients, in 10 trials did not show increased incidence of gastrointestinal bleeding. In 608 patients from six trials the incidence of hyperglycaemia was not increased. 
Results from these data clearly indicate low-dose steroid therapy is safe in septic shock patients.
Studies on low-dose corticosteroid therapy
The debate on low-dose corticosteroid therapy began in the year 2000, with the publication of the study of Annane and others. They studied 189 patients with septic shock and found that patients having baseline plasma cortisol in the level of ≤9 mg/dl, with corticotrophin stimulation, had the best survival rates. 
Another randomised, placebo-controlled, double-blinded trial conducted by Annane and others, in 2002, re-defined the use of low-dose corticosteroid therapy in septic shock patients. A total of 299 patients received either hydrocortisone (50 mg intravenously every six hours) and fludrocortisone (50 mcg tablet once a day) or matching placebos for seven days. Prior to drug administration, the patients received a corticotrophin stimulation test, with two-thirds qualifying as non-responders and the rest as responders. The significant 28-day survival benefit was reported in all patients with corticosteroid responders. The significant 28-day survival benefit was reported in all patients with corticosteroid treatment. A significant improvement in survival was seen primarily in nonresponders. 
The next major study to address this issue was the CORTICUS trial. This study was a randomised, double-blinded, placebo-controlled trial that studied 251 septic shock patients who received 50 mg of intravenous hydrocortisone and 248 septic shock patients who received placebo every six hours, for five days. There was no significant survival benefit in the patients treated with hydrocortisone in comparison to the patients treated with placebo (P=0.69). 
A recent updated meta-analysis published in 2009, indicated the beneficial effect of corticosteroid in septic shock patients, but investigators felt the need for few more research studies in this population of patients. 
Annane and co-workers had published an updated review of their research in the past and concluded that regardless of the dose and duration, the use of corticosteroid was not beneficial in septic shock patients. 
In the year 2008, the most recent Sepsis Survival Campaign Guidelines have downgraded the role of hydrocortisone in the treatment of septic shock to lower the 2C recommendation, and recommended the use of corticosteroid only to those adults whose blood pressure is not responding to adequate fluid management and vasopressor therapy. The SSC guidelines suggest that patients with septic shock must not receive dexamethasone if hydrocortisone is available (grade 2B). Fludrocortisone is considered optional if hydrocortisone is used (grade 2C). In addition they have also discouraged the corticotrophin stimulation test, to identify septic shock patients requiring steroid therapy with a low-grade 2B recommendation. 
| Conclusion|| |
In this era of modern anaesthesia, sepsis remains a challenging and complex disease, despite the advances in conventional critical care. Conventional therapies used in the management of sepsis are not up to the mark, therefore, the search continues for newer modalities. Activated protein C was introduced with new hopes in sepsis management. Although APC has proven its worth in various studies conducted previously, data from recent studies have put a question mark on its efficacy. On the other hand the current use of low-dose corticosteroid therapy is somewhat ambiguous, as it has produced its effect mainly in patients who have developed adrenocortical insufficiency. As per the past studies and recommendations the following can be offered:
- Long duration low-dose hydrocortisone therapy, tapered over a period of at least three to five days, is recommended for septic shock patients not responding to adequate fluid and vasopressor therapy.
- Adult patients with sepsis-induced organ dysfunction associated with a clinical assessment of high risk of death (APACHE II≥25 or multiple organ failure) should receive rhAPC if there are no contraindications.
- Adult patients with severe sepsis and low risk of death (APACHE II<20 or one organ failure) should not be given rhAPC.
- The effects in patients with more than one organ failure, but APACHE II<25, are unclear, and in these circumstance one may use the clinical assessment of the risk of death and the number of organ failures, to support the decision.
| References|| |
|1.||Groveneveld AB, Molenaar N, Beishuizen B. Should we abondan corticosteroid during septic shock? No. Curr Opin Crit Care 2008;14:384-9. |
|2.||Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al. Effectiveness of treatment for severe sepsis: A prospective, multi-center, observational study. Am J Respir Crit Care Med 2009;180:861-6. |
|3.||Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 1995;23:1294-303. |
|4.||American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74. |
|5.||Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6. |
|6.||Asaka S, Shibayama Y, Nakata K. Pathogenesis of focal and random hepatocellular necrosis in endotoxemia: Microscopic observation in vivo. Liver 1996;16:183-7. |
|7.||Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000;20:2511-8. |
|8.||Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-6. |
|9.||Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16. |
|10.||Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001;29:S69-74. |
|11.||Fourrier F, Jourdain M, Tournois A, Caron C, Goudemand J, Chopin C. Coagulation inhibitor substitution during sepsis. Intensive Care Med 1995;21:S264-8. |
|12.||Houston G, Cuthbertson BH. Activated protein C for the treatment of severe sepsis. Clin Microbiol Infect 2009;15:319-24. |
|13.||Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-9. |
|14.||Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001;120:915-22. |
|15.||Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al. Protein C concentrations in severe sepsis: An early directional change in plasma level predicts outcome. Crit Care 2006;10:R92. |
|16.||Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25. |
|17.||Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. |
|18.||Byrnes MC, Beilman GJ. Adjunctive measures for treating surgical infections and sepsis. Surg Clin North Am 2009;89:349-63, viii. |
|19.||Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Drotrecogin Alfa (Activated) for adult with severe sepsis and low risk of death. N Engl J Med 2005;353:1332-41. |
|20.||Nadel S, Goldstein B, Williams MD. Researching severe Sepsis and Organ dysfunction in children: A gLobal perspective (RESOLVE) study group. Drotrecogin Alfa (Activated) in children with severe sepsis: A multicenter phase III randomised controlled trial. Lancet 2007;369:836-43. |
|21.||Marti-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2008;1:CD004388. |
|22.||Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for septic shock. Intensive Care Med 2008;34:1935-47. |
|23.||Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001;29:S99-106. |
|24.||Bφhrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mδnnel D, et al. Role of NF-kB in the mortality of sepsis. J Clin Invest 1997;100:972-85. |
|25.||Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-k B by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-53. |
|26.||Auphan ND, Didonato JA, Rosette C, Heimberg A, Karin M. Immunosupression by glucocorticoid: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90. |
|27.||Hatherill M, Tibby SM, Turner C, Ratnavel N, Murdoch IA. Procalcitonin and cytokine levels: Relationship to organ failure and mortality in pediatric septic shock. Crit Care Med 2000;28:2591-4. |
|28.||Donnelly SC, Strieter RM, Reid PT, Kunkel SL, Burdick MD, Armstrong I, et al. The association between mortality rates and the decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with adult respiratory distress syndrome. Ann Intern Med 1996;125:191-6. |
|29.||Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1191;91:23-9. |
|30.||Presterl E, Staudinger T, Pettermann M, Lassnigg A, Burgmann H, Winkler S, et al. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997;156:825-32. |
|31.||Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, et al. Persistent elevation of inflammatory cytokines predicts poor outcome in ARDS: Plasma IL-1b and IL-6 are consistent and efficient markers of outcome over time. Chest 1995;107:1062-73. |
|32.||Szabo C, Thiemermann C, Wu CC, Perretti M, Vane JR. Attenuation of the induction of nitric oxide synthetase by endogenous glucocorti-coids acconts for endotoxin tolerance in vivo. Proc Nati Acad Sci U S A 1994;91:271-5. |
|33.||Axelrod L. Inhibition of prostacycline production mediates permissive effect of glucocorticoids on vascular tone. Pertubations of this mechanism contribute to pathogenesis of cushing's syndrome and addison's disease. Lancet 1983;1:904-6. |
|34.||Walker BR, Williams BC. Corticosteroids and the vascular tone: Mapping the messenger maze. Clin Sci 1992;82:597-605. |
|35.||Gaillard RC, Turnill D, Sappino P, Muller AF. Tumour necrosis alfa inhibits hormonal response of the pituitary gland to hypothalamic releasing factors. Endocrinology 1990;127:101-6. |
|36.||Jaattela M, Livesmaki V, Voutilainen R, Stenman UH, Saksela E. Tumour necrosis factor factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991;128:623-9. |
|37.||Span LF, Hermus AR, Bartelink AK, Hoitsma AJ, Gimbrθre JS, Smals AG, et al. Adrenocortical function: An indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992;18:93-6. |
|38.||Soni A, Pepper GM, Wyrwinski PM, Ramirez NE, Simon R, Pina T, et al. Adrenal insufficiency occurring during septic shock: Incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995;98:266-71. |
|39.||Annane D. Corticosteroids for septic shock. Crit Care Med 2001;29:S117-20. |
|40.||Keh D, Sprung CL. Use of corticosteroid in therapy in patients with sepsis and septic shock; an evidence based-based review. Crit Care Med 2004;32:5527-33. |
|41.||Oppert M, Reinicke A, Grδf KJ, Barckow D, Frei U, Eckardt KU. Plasma cortisol levels before and during "low-dose" hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock. Intens Care Med 2000;26:1747-55. |
|42.||Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167:512-20. |
|43.||Walker BR, Williams BC. Corticosteroids and vascular tone: Mapping the messenger maze. Clin Sci 1992;82:597-605. |
|44.||Ullian ME. The role of corticosteroids in the regulation of vascular tone. Cardio Res 1999;41:55-64. |
|45.||Annane D, Sιbille V, Charpentier C, Bollaert PE, Franηois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71. |
|46.||Minneci PC, Deans KJ, Banks SM, Eichacker PO, Natanson C. Meta-analysis: The effect of steroids on survival and shock depends on the dose. Ann Intern Med 2004;141:47-56. |
|47.||Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunogenic and hemodynamic effects of low dose hydrocortisone in septic shock; a double-blind, randomized placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167:512-20. |
|48.||Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroid for treating severe sepsis and septic shock. Cochrane Database Syst Rev 2004;1:CD002243. |
|49.||Annane D, Sebille V, Troche G, Raphel JC, Gajdos P, Bellissant E. A3-Level prognostic classification in septic shock based on cortisol level and cortisol response to corticotropin. JAMA 2000;283:1038-45. |
|50.||Annane D, Sιbille V, Charpentier C, Bollaert PE, Franηois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71. |
|51.||Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for the patients with septic shock. N Engl Med 2008;358:111-24. |
|52.||Minnecei PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. The effect of steroid on survival and shock during sepsis depends on the dose and sevearity of illness: An updated meta-analysis: Clin Microbiol Infect 2009;15:308-18. |
|53.||Annane D, Bellissan E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating severe sepsis and septic shock: A systemic review and meta analysis. BMJ 2004;329:480. |
|54.||Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of svere sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327. |